| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Marder, Albert, and Stern), Psychiatry (Drs. Marder and Stern), Sergievsky Center (Drs. Marder, Albert, and Stern), and The Taub Institute for Alzheimer’s Disease and the Aging Brain (Drs. Marder and Stern), Mailman School of Public Health, Columbia University (Dr. Albert), New York; Departments of Biostatistics (Dr. McDermott) and Neurology (Dr. Schifitto, Palumbo, and Kieburtz, C. Orme), University of Rochester, NY; Department of Neurology (Drs. Selnes and Sacktor, J.C. McArthur), Johns Hopkins University, Baltimore, MD; and Departments of Neurology (Dr. Cohen) and Pediatric Neurology (Dr. Epstein), Northwestern University, Evanston, IL.
Address correspondence and reprint requests to Dr. Karen Marder, Sergievsky Center, 630 W. 168th St. Unit 16, New York, NY 10032; e-mail: ksm1{at}columbia.edu
Objective: To determine the inter-rater reliability of a modification of the Memorial Sloan-Kettering (MSK) Staging for HIV-associated cognitive impairment.
Methods: Data were abstracted on neurologic, neuropsychological, and functional status on 100 individuals participating at four sites in the Northeast AIDS Dementia (NEAD) Consortium cohort study, a longitudinal study of predictors of cognitive impairment in HIV-infected individuals. Neuropsychological performance was defined 1) based on the neuropsychologist’s global impression and 2) solely based on neuropsychological test scores. Raters at each site used the abstracted data to assign an MSK stage to each subject blind to any identifying information. Inter-rater reliability was assessed using kappa statistics. Agreement between computer-generated ratings and site-generated ratings was also assessed.
Results: Kappa statistics for pair-wise agreement among the sites regarding MSK stage ranged from 0.70–0.91, representing good to excellent agreement between sites. Agreement between computer-generated ratings and site-generated ratings was in the good to excellent range (0.62–0.79).
Conclusions: The authors have modified the MSK rating scale and developed a reliable instrument that can be used in multicenter studies. This instrument will be useful in staging HIV-dementia in future longitudinal studies and will be valuable in increasing accuracy of clinicopathologic studies.
This article has been cited by other articles:
|
|
 |
|
  Y. Wu, P. Storey, A. Carrillo, C. Saglamer, B.A. Cohen, L.G. Epstein, R.R. Edelman, and A.B. Ragin Whole Brain and Localized Magnetization Transfer Measurements Are Associated with Cognitive Impairment in Patients Infected with Human Immunodeficiency Virus AJNR Am. J. Neuroradiol., January 1, 2008; 29(1): 140 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment Neurology, September 25, 2007; 69(13): 1314 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Sui, L. F. Sniderhan, G. Schifitto, R. P. Phipps, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar Functional Synergy between CD40 Ligand and HIV-1 Tat Contributes to Inflammation: Implications in HIV Type 1 Dementia J. Immunol., March 1, 2007; 178(5): 3226 - 3236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Ances, A. C. Roc, J. Wang, M. Korczykowski, J. Okawa, J. Stern, J. Kim, R. Wolf, K. Lawler, D. L. Kolson, et al. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients Neurology, March 28, 2006; 66(6): 862 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.B. Ragin, Y. Wu, P. Storey, B.A. Cohen, R.R. Edelman, L.G. Epstein, and S. Gartner Bone Marrow Diffusion Measures Correlate with Dementia Severity in HIV Patients AJNR Am. J. Neuroradiol., March 1, 2006; 27(3): 589 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, P. Storey, B.A. Cohen, L.G. Epstein, R.R. Edelman, and A.B. Ragin Diffusion Alterations in Corpus Callosum of Patients with HIV AJNR Am. J. Neuroradiol., March 1, 2006; 27(3): 656 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Ragin, P. Storey, B. A. Cohen, R. R. Edelman, and L. G. Epstein Disease burden in HIV-associated cognitive impairment: A study of whole-brain imaging measures Neurology, December 28, 2004; 63(12): 2293 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Sevigny, S. M. Albert, M. P. McDermott, J. C. McArthur, N. Sacktor, K. Conant, G. Schifitto, O. A. Selnes, Y. Stern, D. R. McClernon, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia Neurology, December 14, 2004; 63(11): 2084 - 2090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. McArthur, M. P. McDermott, D. McClernon, C. St Hillaire, K. Conant, K. Marder, G. Schifitto, O. A. Selnes, N. Sacktor, Y. Stern, et al. Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy Arch Neurol, November 1, 2004; 61(11): 1687 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Valcour, C. Shikuma, B. Shiramizu, M. Watters, P. Poff, O. Selnes, P. Holck, J. Grove, and N. Sacktor Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort Neurology, September 14, 2004; 63(5): 822 - 827. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
